Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | CA7 | P43166 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CTSK | P43235 | 11/20 | 0.45 |
| ▸ | CTSS | P25774 | 6/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | CTSL | P07711 | 2/20 | 0.40 |
| ▸ | CTSB | P07858 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | APLNR | P35414 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL56783 | 1.00 | CA1 (0.53) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL4574028 | 1.00 | CA1 (0.53) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL3685399 | 0.86 | CA1 (0.47) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL23925023 | 0.86 | CA1 (0.47) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL14496991 | 0.86 | CA1 (0.47) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL1352540 | 0.85 | CA1 (0.46) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL31255051 | 0.85 | CA1 (0.46) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL1692753 | 0.85 | CA1 (0.46) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL22362992 | 0.85 | CA1 (0.46) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL30365028 | 0.85 | CA1 (0.46) | CA1CA2CA7CYP2D6CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119613701-A | Method for synthesizing functionalized polyether in multi-proton system | 华南理工大学 | 2025-03-14 | — | — | CN | disclosed |
| CN-113166143-B | N-1 branched alkyl ether substituted imidazo [4,5-c ] quinoline compounds, compositions and methods | 舒万诺知识产权公司 | 2024-06-04 | — | — | CN | disclosed |
| US-20240174662-A1 | SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES | CILAG AG (CH) | 2024-05-30 | — | — | US | disclosed |
| EP-3887369-B1 | N-1 BRANCHED ALKYL ETHER SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS, COMPOSITIONS, AND METHODS | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) | 2024-05-08 | — | — | EP | disclosed |
| EP-4284802-A1 | SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES | Janssen Biotech, Inc. (US) | 2023-12-06 | — | — | EP | disclosed |
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-07-06 | — | — | US | disclosed |
| WO-2023036156-A1 | DNA-PK SELECTIVE INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 首药控股(北京)股份有限公司 | 2023-03-16 | — | — | WO | disclosed |
| WO-2022165530-A1 | SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES | JANSSEN BIOTECH, INC. (US) | 2022-08-04 | — | — | WO | disclosed |
| CN-110526930-B | anti-HIV (human immunodeficiency virus) sulfur-containing polycyclic-hydroxypyridone formamide analogue and application thereof | 莫云芬 | 2022-06-03 | — | — | CN | disclosed |
| EP-3980415-A1 | N-1 BRANCHED ALKYL SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS, COMPOSITIONS, AND METHODS | 3M Innovative Properties Company (US) | 2022-04-13 | — | — | EP | disclosed |
| US-7186747-B2 | Compounds as inhibitors of hepatitis C virus NS3 serine protease | SCHERING CORPORATION (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186747-B2 | Compounds as inhibitors of hepatitis C virus NS3 serine protease | SCHERING CORPORATION (US) | 2007-03-06 | — | — | US | disclosed |
| US-20050272663-A1 | Novel substituted prolines as inhibitors of hepatitis C virus NS3 serine protease | SCHERING CORPORATION | 2005-12-08 | — | — | US | disclosed |
| WO-2005113581-A1 | SUBSTITUTED PROLINES AS INHIBITORS OF HEPATITIS C VIRUS NS3 SERINE PROTEASE | SCHERING CORPORATION (US) | 2005-12-01 | — | — | WO | disclosed |
| WO-2005113581-A1 | SUBSTITUTED PROLINES AS INHIBITORS OF HEPATITIS C VIRUS NS3 SERINE PROTEASE | SCHERING CORPORATION (US) | 2005-12-01 | — | — | WO | disclosed |
| WO-2005087725-A2 | NOVEL COMPOUNDS AS INHIBITORS OF HEPATITIS C VIRUS NS3 SERINE PROTEASE | SCHERING CORPORATION (US) | 2005-09-22 | — | — | WO | disclosed |
| WO-2005087730-A1 | 3,4-(CYCLOPENTYL)-FUSED PROLINE COMPOUNDS AS INHIBITORS OF HEPATITIS C VIRUS NS3 SERINE PROTEASE | SCHERING CORPORATION (US) | 2005-09-22 | — | — | WO | disclosed |
| WO-2005085242-A1 | NOVEL KETOAMIDES WITH CYCLIC P4'S AS INHIBITORS OF NS3 SERINE PROTEASE OF HEPATITIS C VIRUS | SCHERING CORPORATION (US) | 2005-09-15 | — | — | WO | disclosed |
| WO-2005030796-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS NS3 SERINE PROTEASE | SCHERING CORPORATION (US) | 2005-04-07 | — | — | WO | disclosed |
| WO-2005021584-A2 | NOVEL PEPTIDOMIMETIC NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | SCHERING CORPORATION (US) | 2005-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272663-A1 | Novel substituted prolines as inhibitors of hepatitis C virus NS3 serine protease | PREP, HPN, PEPD | CA1 3261/4885CA2 4081/4885CA7 4295/4885 |
| US-20240174662-A1 | SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES | SIK2, SIK1, SGK2 | CA1 1900/4885CA2 534/4885CA7 1632/4885 |
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTRL, CTSL, CTSV | CA1 545/4885CA2 607/4885CA7 627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.